{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:01:11Z","timestamp":1792144871155,"version":"4.4.0"},"reference-count":98,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emerging evidence suggests that dual targeted therapy (DTT), which employs two biologics or small molecules concurrently, may improve outcomes for patients with refractory inflammatory bowel disease (IBD). We conducted a systematic review and meta\u2010analysis to assess the efficacy and safety of DTT, with a comparative evaluation of different combination therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched MEDLINE, Embase, Cochrane Library, CBM, CNKI, VIP, and WanFang from inception to March 8, 2026. Eligible studies were clinical trials or cohort studies reporting DTT outcomes in IBD. Efficacy outcomes included clinical response, clinical remission, clinical improvement, and endoscopic improvement; safety outcomes included adverse events (AEs) and serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty\u2010three studies comprising 2097 patients were included. Overall, DTT exhibited promising efficacy in refractory IBD, with pooled clinical response and remission rates of 68.0% (95% confidence interval [CI], 62.7%\u201372.8%) and 50.7% (95% CI, 44.2%\u201357.1%), respectively. Antitumor necrosis factor \u03b1 (TNF\u03b1) plus IL\u201012\/23 inhibitors was associated with higher clinical improvement than anti\u2010TNF\u03b1 plus anti\u2010integrin therapy (odds ratio [OR] = 4.74; 95% CI, 2.31\u20139.73) and anti\u2010integrin plus Janus kinase inhibitors (OR = 17.52; 95% CI, 1.09\u2013281.12) in IBD patients. The safety profile of DTT was acceptable, with pooled rates of AEs and SAEs being 28.2% (95% CI, 21.9%\u201335.5%) and 8.3% (95% CI, 6.3%\u201310.8%), respectively. Notably, anti\u2010integrin plus IL\u201012\/23 inhibitors showed lower AE rates than anti\u2010TNF\u03b1 plus IL\u201012\/23 inhibitors (OR = 0.19; 95% CI, 0.06\u20130.65).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DTT shows promising efficacy with an acceptable safety profile in refractory IBD. Large\u2010scale, high\u2010quality studies are required to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jebm.70157","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:22:20Z","timestamp":1782922940000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual Targeted Therapy for Refractory Inflammatory Bowel Disease: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","volume":"19","author":[{"given":"Chenyue","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University  Beijing China"},{"name":"State Key Laboratory of Digestive Health  Beijing China"},{"name":"National Clinical Research Center for Digestive Disease  Beijing China"},{"name":"Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103498"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad203"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i41.4411"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00593-y"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae145"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx110"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.841"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(20)33683-0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12867"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000705636.81939.0a"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00396-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15719"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab112"},{"issue":"9","key":"e_1_2_7_21_1","first-page":"1953","article-title":"Evaluation of the Safety of Vedolizumab in Combination With Other Immunosuppression Biological Therapy in Patients With Inflammatory Bowel Disease","volume":"73","author":"Chesini G.","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa277"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12170"},{"issue":"1","key":"e_1_2_7_24_1","first-page":"S235","article-title":"Safety and Efficacy of Combining Biologicals in Children With Inflammatory Bowel Disease","volume":"73","author":"Goyal A.","year":"2021","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab028"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.02.017"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab030"},{"issue":"8","key":"e_1_2_7_28_1","first-page":"576","article-title":"Biologics and Small Molecules Combotherapies: Promising Experience in Refractory ibd Patients","volume":"9","author":"Martinho M.","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa149"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000798904.09135.49"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac015.168"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2045350"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000860716.95131.a3"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab176"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.217"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(23)03612-0"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.09.010"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwad061.231"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0876"},{"issue":"1","key":"e_1_2_7_40_1","first-page":"A121","article-title":"Shifting Paradigms: A Single Trust Experience of Combination Biologic or Small Molecule Therapy for IBD","volume":"73","author":"Hazel K.","year":"2024","journal-title":"Gut"},{"issue":"7","key":"e_1_2_7_41_1","first-page":"476","article-title":"Efficacy and Safety of Dual Biological Agents in the Treatment of Refractory Inflammatory Bowel Disease","volume":"44","author":"Dongdong H.","year":"2024","journal-title":"Chinese Journal of Digestive Diseases"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(24)03096-8"},{"key":"e_1_2_7_43_1","first-page":"3S","article-title":"Advanced Therapies, the Best Combinations in Refractory IBD Patients","volume":"154","author":"Juillerat P.","year":"2024","journal-title":"Swiss Medical Weekly"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08379-9"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.08.055"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08182-y"},{"key":"e_1_2_7_47_1","first-page":"244","article-title":"Efficacy of Combination Vedolizumab and Upadacitinib Treatment in Refractory Inflammatory Bowel Disease: A Case Series","volume":"39","author":"Swe E. P. P.","year":"2024","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001034236.08316.18"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12179"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad064"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae105"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001135200.71215.74"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae057"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70077"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70298"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70059"},{"key":"e_1_2_7_57_1","unstructured":"E. N.Fear B. D.McDonald R. H.McMillan et\u00a0al. \u201cDual\u2010Targeted Therapy with Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD \u201dGastroenterology and Hepatology21 no. 7 Suppl 5 (2025):15\u201316."},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(25)02269-3"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00174"},{"issue":"1","key":"e_1_2_7_60_1","first-page":"75","article-title":"Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience","volume":"12","author":"Guo C.","year":"2025","journal-title":"Children (Basel)"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0973"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S511309"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1566828"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70198"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.070"},{"key":"e_1_2_7_66_1","first-page":"i2514","article-title":"One\u2010Year Outcomes of Advanced Combination Therapy in Refractory Inflammatory Bowel Disease","volume":"20","author":"Rodriguez Gallardo M.","year":"2026","journal-title":"Journal of Crohn's and Colitis"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.1359"},{"issue":"1","key":"e_1_2_7_68_1","first-page":"i2153","article-title":"Combining Guselkumab With Upadacitinib Demonstrates Efficacy in Medically Complex Crohn's Disease","volume":"20","author":"Natt N.","year":"2026","journal-title":"Journal of Crohn's and Colitis"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70309"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003573"},{"issue":"1","key":"e_1_2_7_71_1","first-page":"i1611","article-title":"Safety Profile of Upadacitinib in Inflammatory Bowel Disease: Insights From FAERS Database and Single\u2010Center Clinical Data Background","volume":"20","author":"Wei T.","year":"2026","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"e_1_2_7_72_1","first-page":"i4","article-title":"Efficacy and Safety of Vedolizumab Combined With Upadacitinib as an 8\u2010Week Induction Strategy in Moderate\u2010to\u2010Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial","volume":"20","author":"Wu H.","year":"2026","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"e_1_2_7_73_1","first-page":"i1991","article-title":"Dual Targeted Therapy With Vedolizumab and Tofacitinib in Patients With Ulcerative Colitis: Initial Results From the Phase 4 ExiGem Study","volume":"20","author":"Yarur A.","year":"2026","journal-title":"Journal of Crohn's and Colitis"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.034"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1597159"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07837-0"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac002"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf188"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwad032"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225318"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i22.2902"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306518"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315671"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(22)61876-6"},{"issue":"3","key":"e_1_2_7_86_1","first-page":"206","article-title":"New Progress on the Use of Dual Biologic Therapy for Patients With Inflammatory Bowel Disease","volume":"39","author":"Liu Y.","year":"2023","journal-title":"Clinical Medicine of China"},{"issue":"4","key":"e_1_2_7_87_1","article-title":"Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles","volume":"9","author":"Nemeth Z. H.","year":"2017","journal-title":"Cureus"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21248"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310022"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780040406"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2024.06.006"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab257"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15706"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-008-0062-1"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.279"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01840-5"}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jebm.70157","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:03:00Z","timestamp":1790326980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jebm.70157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jebm.70157"],"URL":"https:\/\/doi.org\/10.1111\/jebm.70157","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2025-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70157"}}